U.S. markets open in 8 hours 29 minutes

Galmed Pharmaceuticals Ltd. (GLMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.4100-0.1700 (-6.59%)
At close: 4:00PM EDT

Galmed Pharmaceuticals Ltd.

16 Tiomkin Street
Tel Aviv 6578317
Israel
972 3 693 8448
http://www.galmedpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees18

Key Executives

NameTitlePayExercisedYear Born
Mr. Allen BaharaffCo-Founder, Pres, CEO & Chairman766.58kN/A1965
Mr. Yohai StenzlerChief Financial Officer167.26kN/A1983
Mr. Guy NehemyaChief Operating Officer167.54kN/A1985
Dr. Liat HayardenyChief Scientific Officer215.45kN/A1967
Dr. Tali GorfineMedical Consultant202.76kN/A1970
Ms. Yael HollanderVP of Legal Affairs & StrategyN/AN/A1983
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

Corporate Governance

Galmed Pharmaceuticals Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.